Transcutaneous Spinal Cord Stimulation for Motor Recovery After Spinal Cord Injury

November 13, 2026 updated by: Dr. Gabriel Zeilig

Restoring Upper and Lower Extremity Functions in Persons With Spinal Cord Injury by Transcutaneous Spinal Cord Stimulation

This study will examine the safety, feasibility, and potential benefits of transcutaneous spinal cord stimulation (scTS) combined with activity-based training in people with spinal cord injury.

The study will include 10 adults with chronic, incomplete spinal cord injury. Electrical stimulation will be delivered through electrodes placed on the skin over different regions of the spinal cord, while participants perform exercises involving the arms, hands, trunk, and legs.

Participants will undergo initial assessments, individualized stimulation mapping, and 80 training sessions, followed by final assessments. Researchers will evaluate changes in motor function, muscle activity, psychological well-being, autonomic function, and quality of life. Safety and tolerability will also be monitored throughout the study.

Study Overview

Detailed Description

This prospective, single-arm, within-subject exploratory study will enroll 10 adults aged 18-65 years with chronic incomplete cervical or thoracic spinal cord injury.

The study includes four phases: (1) baseline assessments over approximately two months; (2) stimulation mapping and optimization over approximately 0.5-1 month to identify individualized stimulation parameters; (3) 80 sessions of multisegment transcutaneous spinal cord stimulation combined with activity-based training, delivered 3-5 days per week over approximately 4-7 months; and (4) follow-up assessments.

The intervention targets upper and lower extremity function, trunk control, standing, and stepping. Motor performance will be assessed primarily using the Neuromuscular Recovery Scale (NRS). Additional assessments will examine muscle activation using electromyography (EMG), psychological symptoms, autonomic function, neurological status, spasticity, functional independence, and quality of life.

Intermediate assessments will be conducted during the intervention, including after 40 training sessions. Safety, adverse events, and feasibility will be evaluated throughout the study.

Study Type

Interventional

Enrollment (Estimated)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Ramat Gan, Israel
        • Sheba Medical Center
        • Contact:
        • Sub-Investigator:
          • Einat Haber, M.D.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. At least 18 years of age.
  2. Non-progressive cervical or thoracic (>T10) spinal cord injury (SCI), with the ability to voluntarily move at least three joints below the injury level.
  3. At least 6 months post spinal cord injury.
  4. Stable medical condition.
  5. Neuromuscular Recovery Scale (NRS) score <4C on any upper extremity, trunk, or standing/stepping item.

Exclusion Criteria:

  1. Ventilator dependence.
  2. Untreated or unstable fracture or pressure ulcer.
  3. Untreated psychiatric disorder or ongoing drug abuse.
  4. Cardiac, respiratory, bladder, renal, or other medical disorder that may interfere with the study.
  5. Skeletal muscle Botox injections within the previous 6 months.
  6. Previous nerve or tendon transfer of the arms or legs.
  7. Any implanted pump (e.g., baclofen pump or pain pump).
  8. Unable or unwilling to discontinue anti-spasticity medications.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Multisegment scTS + Activity-Based Training

Participants will receive individualized multisegment transcutaneous spinal cord stimulation (scTS) combined with activity-based training targeting upper and lower extremity function, trunk control, standing, and stepping. The intervention will consist of 80 training sessions, delivered 3-5 days per week over approximately 4-7 months, with sessions lasting up to 2 hours.

Non-invasive electrical stimulation delivered through surface electrodes placed over multiple spinal levels using the NeoStim-5 system. Stimulation sites and parameters will be individually optimized to facilitate motor activation of the upper extremities, trunk, and lower extremities during activity-based training.

Individualized, task-specific rehabilitation training targeting voluntary control of the hands, arms, trunk, and legs, including seated activities, standing, and stepping. Training will be provided by rehabilitation staff and combined with transcutaneous spinal cord stimulation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Motor Function (NRS)
Time Frame: Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).

Changes in motor performance assessed using the Neuromuscular Recovery Scale (NRS), which evaluates movement quality and the level of assistance required during upper extremity, trunk, standing, and stepping tasks. Changes in individual task ratings will be assessed across study time points.

Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).
Safety
Time Frame: From enrollment through the final study assessment (approximately 7-10 months per participant).

Incidence of adverse events and equipment-related complications during the study. Adverse events will be categorized by severity, relatedness to study procedures, and expectedness.

From enrollment through the final study assessment (approximately 7-10 months per participant).

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Surface EMG Amplitude During Functional Motor Tasks
Time Frame: Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).

Changes in surface electromyography (EMG) signal amplitude during functional motor tasks involving upper extremity, trunk, and lower extremity muscles.

Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).
Depression (PHQ-9)
Time Frame: Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).

Changes in depressive symptoms measured using the 9-item Patient Health Questionnaire (PHQ-9). Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity.

Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).
Anxiety (GAD-7)
Time Frame: Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).

Changes in anxiety symptoms measured using the 7-item Generalized Anxiety Disorder scale (GAD-7). Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity.

Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).
PTSD (PCL-5)
Time Frame: Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training)

Changes in self-reported post-traumatic stress symptoms measured using the PTSD Checklist for DSM-5 (PCL-5). Total scores range from 0 to 80, with higher scores indicating greater symptom severity.

Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training)
PTSD (CAPS-5)
Time Frame: Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).

Changes in clinician-rated post-traumatic stress symptom severity measured using the CAPS-5. The total severity score ranges from 0 to 80, with higher scores indicating greater symptom severity.

Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).
Change in ISNCSCI Total Motor Score
Time Frame: Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)

Change in motor function assessed using the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI). The total motor score ranges from 0 to 100, with higher scores indicating better motor function.

Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)
Change in Modified Ashworth Scale (MAS) Score
Time Frame: Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)

Change in muscle spasticity assessed by a clinician using the Modified Ashworth Scale, which grades resistance to passive movement.

Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)
Change in Spinal Cord Injury Spasticity Evaluation Tool (SCI-SET) Score
Time Frame: Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)

Change in the self-reported impact of spasticity on daily activities, assessed using the SCI-SET questionnaire covering the preceding seven days.

Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)
Change in Autonomic Dysfunction Following Spinal Cord Injury (ADFSCI) Questionnaire Score
Time Frame: Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)

Change in frequency and severity of symptoms associated with blood pressure instability, assessed using the 24-item ADFSCI questionnaire.

Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)
Change in Modified Functional Reach Test Distance
Time Frame: Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)

Change in maximum forward reaching distance while seated, measured using the Modified Functional Reach Test

Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)
Change in Activity-Based Balance Level (ABLE) Sitting Subscale Score
Time Frame: Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)

Change in sitting balance assessed using the seven items of the ABLE sitting subscale, with a maximum score of 32.

Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

January 1, 2029

Study Completion (Estimated)

January 1, 2030

Study Registration Dates

First Submitted

November 8, 2026

First Submitted That Met QC Criteria

November 13, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe